Tracon Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — TRACON receives Nasdaq notice for market value below $35M; 180-day cure period

Tracon Pharmaceuticals, Inc.

On Dec 30, 2022, Nasdaq notified TRACON that its common stock market value was below $35M for 30 consecutive business days.
Company has until June 28, 2023 to regain compliance by having market value >=$35M for 10 consecutive business days.
Alternative compliance: stockholders' equity >=$2.5M or net income from continuing operations of $500,000 in most recent fiscal year.
Failure may result in delisting; company evaluating potential actions to regain compliance but no assurance.
TCON continues trading on Nasdaq during grace period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Tracon Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

December 30, 2022, TRACON Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the market value of the Company’s common stock was less than $35.0 million, which does not meet the requirement for continued listing on the Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provi

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001564590-22-040087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.